Shots:

• The P-III ADVANCE & MOTIVATE studies involves assessing of Risankizumab (600/1200mg) vs PBO in adult patients with mod. to sev. CD who had an inadequate response/ were intolerant to conventional and/or biologic therapy & patients who had responded inadequately or were intolerant to biologic therapy respectively
• Results: @12wks. clinical remission as per CDAI (45%/42% vs 25%) & (42%/41% vs 19%); clinical remission per PRO-2 (43%/41% vs 21%) & (35%/39% vs 19%); endoscopic response (40%/32% vs 12%) & (29%/34% vs 11%) respectively
• Skyrizi is an IL-23 inhibitor- being evaluated in mod. to sev. CD and other immune-mediated conditions

 ­ Ref: AbbVie| Image:abbvie